Arno Financial Statements From 2010 to 2025
| ARNI Stock | USD 0.0002 0.00 0.00% |
Check Arno Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arno Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Arno financial statements analysis is a perfect complement when working with Arno Therapeutics Valuation or Volatility modules.
Arno |
Arno Therapeutics OTC Stock Price To Earning Analysis
Arno Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Arno Therapeutics Price To Earning | (0.11) X |
Most of Arno Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arno Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Arno Therapeutics has a Price To Earning of -0.11 times. This is 100.43% lower than that of the Biotechnology sector and 102.23% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.38% higher than that of the company.
Arno Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arno Therapeutics's current stock value. Our valuation model uses many indicators to compare Arno Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arno Therapeutics competition to find correlations between indicators driving Arno Therapeutics's intrinsic value. More Info.Arno Therapeutics is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Arno Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Arno Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Arno Therapeutics Financial Statements
Investors use fundamental indicators, such as Arno Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Arno Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company has license agreements with Invivis Pharmaceuticals, Inc. the Regents of the University of Minnesota and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. ARNO THERAPEUTICS operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 4 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Arno OTC Stock
Arno Therapeutics financial ratios help investors to determine whether Arno OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Arno with respect to the benefits of owning Arno Therapeutics security.